An EGFR mutation-positive advanced or metastatic NSCLC rural resident patient had to spend 10–15 months of salary to pay the OOP expenditure of icotinib or gefitinib for the median progression-free survival time (10 months). Here, EGFR is linked to non-small cell lung carcinoma.